Suyash Prasad Sells 8,000 Shares of Audentes Therapeutics Inc (BOLD) Stock

Audentes Therapeutics Inc (NASDAQ:BOLD) VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $28.53, for a total transaction of $228,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Audentes Therapeutics Inc (NASDAQ:BOLD) traded up $0.05 during mid-day trading on Thursday, hitting $27.43. 134,600 shares of the company traded hands, compared to its average volume of 148,030. Audentes Therapeutics Inc has a twelve month low of $13.90 and a twelve month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, hitting the consensus estimate of ($0.88). analysts anticipate that Audentes Therapeutics Inc will post -3.52 EPS for the current year.

Several research firms have recently weighed in on BOLD. ValuEngine downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Raymond James Financial began coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They issued a “market perform” rating on the stock. BMO Capital Markets began coverage on shares of Audentes Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $35.00 target price on the stock. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. Finally, Bank of America reissued a “buy” rating and issued a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $28.29.

Hedge funds have recently bought and sold shares of the stock. Redmile Group LLC lifted its stake in Audentes Therapeutics by 77.8% in the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after acquiring an additional 638,780 shares during the last quarter. Jennison Associates LLC lifted its stake in Audentes Therapeutics by 182.4% in the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after acquiring an additional 546,617 shares during the last quarter. Vanguard Group Inc. lifted its stake in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after acquiring an additional 383,837 shares during the last quarter. Artal Group S.A. acquired a new stake in Audentes Therapeutics in the third quarter valued at approximately $5,602,000. Finally, State Street Corp lifted its stake in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after acquiring an additional 154,544 shares during the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/07/suyash-prasad-sells-8000-shares-of-audentes-therapeutics-inc-bold-stock.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply